Arrakis Therapeutics

First-in-class small molecule modulators of RNA

Arrakis is building a proprietary platform to enable the rational, structure-based design of orally acting small molecules that bind RNA, and so directly modulate RNA function.

CEO  Michael Gilman

arrakistx.com

Advent Contact  Raj Parekh

Advent founded Arrakis in 2014.
Private Companies
5 December 2024 in Arrakis Therapeutics, Press Release, Private Companies

Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to Treat Myotonic Dystrophy

Press Release.   Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to Treat Myotonic Dystrophy Preclinical data presented…
Read More
11 January 2022 in Arrakis Therapeutics, Press Release, Private Companies

Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics

Press Release.   Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics Collaboration Creates “Targeted RNA Degraders” by Bringing Together Amgen’s Induced Proximity Platform…
Read More
8 April 2020 in Arrakis Therapeutics, Press Release, Private Companies

Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform

Press Release.   Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform Arrakis Receives $190 Million Upfront Cash Payment…
Read More
18 April 2019 in Arrakis Therapeutics, Press Release, Private Companies

Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA

Press Release.   April 18, 2019 Michael Gilman, Ph.D., to expand role to full-time CEO to lead company to clinical stage Having established first-in-industry RNA-targeted Small Molecule (rSM) platform, Arrakis…
Read More
27 February 2017 in Arrakis Therapeutics, Press Release, Private Companies

Arrakis Therapeutics Announces $38M Series A Financing To Target RNA with Small-Molecule Medicines And Names Michael Gilman Chairman and CEO

Press Release.   Veteran management team to re-architect small molecule drug discovery to pursue new RNA targets within vast human transcriptome Waltham, Mass., February 27, 2017 – Arrakis Therapeutics, a…
Read More